DEA Pushes for CAMU-Based Reclassification of Cannabis at Rescheduling Hearing

At a two-week administrative hearing, the DEA urged that cannabis be moved from Schedule I toward Schedule III by showing it has currently accepted medical use (CAMU) based on FDA/HHS analysis and clinical data; anti-rescheduling groups contested the CAMU framework and the traditional five-factor test. The proceedings feature FDA scientist Dominic Chiapperino and cross-examinations, with the outcome expected to emerge later in the process.